All In Biotech

Drug Trial Radar · NCT06605963

PPV-06 Vaccine in Inflammatory Knee Osteoarthritis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of PPV-06 Active Immunotherapy in Patients With Inflammatory Knee Osteoarthritis (KOA)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

204

Planned (sponsor's estimate)

Start

Apr 2027

Primary completion

Dec 2030

Study completion Dec 2030

Sponsor

Lead sponsor
Peptinov SASIndustry
Sponsor type
Industry
First posted
Sep 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PPV-06 targets interleukin-6, a key molecule implicated in many inflammatory diseases such osteoarthritis. PPV-06 is used to induce the production of antibodies directed against IL-6. The antibodies produced will neutralize the interleukine-6 involved in the body's inflammatory process. The goal of this clinical trial is to test the safety and efficacy of PPV-06 in participants with Knee Osteoarthritis. The main questions are to evaluate if PPV-06 can reduce pain and improve functioning in participants with knee osteoarthritis, and to evaluate if ¨PPV-06 is safe when administered to participants. Participants will be administered with 6 subcutaneous injections of either PPV-06 or placebo, over a two-year period.

Conditions

  • Osteoarthritis, Knee

Interventions

  • PPV-06Drug

    6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84

  • PlaceboDrug

    6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of PPV-06 on pain in participants with knee OsteoarthritisTime frame: From Baseline to Week 54
  2. To evaluate the efficacy of PPV-06 on physical functioning in participants with knee OsteoarthritisTime frame: From Baseline to Week 54

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CIC Cochin

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.